Lung Cancer Panel 6 [EGFR by Sequencing,ALK by IHC, ROS1 by FISH] Test
Short Name: Lung Cancer Panel 6
Also known as: Lung Cancer Panel 6, EGFR ALK ROS1 Panel, Lung Cancer Mutation Panel
Lung Cancer Panel 6 [EGFR by Sequencing,ALK by IHC, ROS1 by FISH] Test test available at DNA Labs India for ₹30,000. Uses Sanger Sequencing, Immunohistochemistry (IHC), Fluorescence In Situ Hybridization (FISH) on Tumor tissue (paraffin-embedded block) samples. Results in Results are typically available within 5-7 working days after the laboratory receives the sample.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr Pasupathy Arumugam
Consultant Pathologist · Reg: 21521
Last reviewed: September 7, 2026
Overview
The purpose of the Lung Cancer Panel 6 is to detect specific genetic alterations in tumor tissue that are actionable with targeted therapies. EGFR mutations (exons 18-21) predict response to EGFR TKIs such as erlotinib, gefitinib, and osimertinib. ALK rearrangements (most commonly EML4-ALK) indicate sensitivity to ALK inhibitors like crizotinib, ceritinib, and alectinib. ROS1 fusions respond to crizotinib and entrectinib. Identifying these biomarkers helps in selecting the optimal first-line therapy, avoiding unnecessary toxicity, and improving progression-free survival. Additionally, the test aids in prognostic stratification and clinical trial eligibility.
- Test Code
- 6124
- CPT Code
- 81445
- ICD Code
- C34.90
- Price
- ₹30,000
- Sample Type
- Tumor tissue (paraffin-embedded block)
- Result Time
- Results are typically available within 5-7 working days after the laboratory receives the sample.
- Fasting Required
- No
- Method
- Sanger Sequencing, Immunohistochemistry (IHC), Fluorescence In Situ Hybridization (FISH)
Sample Collection
No special preparation required. A doctor's prescription is mandatory. Inform your physician about any medications you are taking.
Method: Biopsy or surgical resection
Laboratory Analysis
The sample is collected via biopsy or surgical resection. The procedure is performed by a qualified healthcare professional.
Report Delivery
The tissue sample is placed in a sterile container with formalin or as a paraffin block. It is then transported to the laboratory for analysis.
Timeline: Results are typically available within 5-7 working days after the laboratory receives the sample.
Patient Instructions
About This Test
Who Should Get This Test
The purpose of the Lung Cancer Panel 6 is to detect specific genetic alterations in tumor tissue that are actionable with targeted therapies. EGFR mutations (exons 18-21) predict response to EGFR TKIs such as erlotinib, gefitinib, and osimertinib. ALK rearrangements (most commonly EML4-ALK) indicate sensitivity to ALK inhibitors like crizotinib, ceritinib, and alectinib. ROS1 fusions respond to crizotinib and entrectinib. Identifying these biomarkers helps in selecting the optimal first-line therapy, avoiding unnecessary toxicity, and improving progression-free survival. Additionally, the test aids in prognostic stratification and clinical trial eligibility.
How to Prepare
- Tissue sample must be obtained from a biopsy or surgical resection
- Sample should be fixed in 10% neutral buffered formalin
- Paraffin-embedded tissue block or unstained slides are acceptable
- Ensure adequate tumor cellularity (at least 20%)
- Label the sample with patient identification and date
Doctor's Notes
Reviewed by Dr Pasupathy Arumugam — MBBS, MD (Pathology) · Reg. No. 21521
"This panel is essential for guiding targeted therapy in non-small cell lung cancer. Detection of EGFR mutations, ALK rearrangements, and ROS1 fusions helps select appropriate tyrosine kinase inhibitors, improving patient outcomes."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Inadequate tumor content (<20%)
- Sample not fixed properly
- Decalcified tissue (may degrade DNA)
- Insufficient tissue volume
- Sample without proper labeling or requisition form
Understanding Your Results
Mutation detected
Eligible for EGFR TKIs (e.g., osimertinib, erlotinib)
No mutation detected
EGFR TKIs unlikely to be effective
Positive (IHC 2+/3+)
Eligible for ALK inhibitors (e.g., crizotinib, alectinib)
Negative
ALK inhibitors not indicated
Rearrangement positive
Eligible for ROS1 inhibitors (e.g., crizotinib, entrectinib)
Rearrangement negative
ROS1 inhibitors not indicated
Consult your oncologist if you have been diagnosed with lung cancer and are considering targeted therapy. Also, if you experience new or worsening symptoms such as persistent cough, chest pain, or unexplained weight loss, seek medical advice.
Limitations
- ⚠Sanger sequencing may miss low-level mutations (<20% allele frequency)
- ⚠IHC for ALK may have false positives/negatives; confirmation with FISH may be needed
- ⚠FISH for ROS1 may miss some fusion variants
- ⚠Test is performed on tumor tissue; liquid biopsy not included
- ⚠Results are qualitative; not for monitoring minimal residual disease
Risks & Considerations
- ●Biopsy procedure carries a small risk of bleeding, infection, or pneumothorax
- ●Rare false-positive or false-negative results
- ●Inconclusive results due to insufficient tissue
Interfering Factors
- ●Inadequate tumor content (<20%) in the sample
- ●Poor tissue fixation or decalcification
- ●Necrotic or degraded DNA/RNA
- ●Previous chemotherapy or radiation may alter biomarker expression
- ●Rare false positives/negatives due to technical limitations
Compare With Similar Tests
| Test | Lung Cancer Panel 6 [EGFR by Sequencing,ALK by IHC, ROS1 by FISH] | Lung Cancer Panel 6 | Lung Cancer Panel 5 | Lung Cancer Panel 8 |
|---|---|---|---|---|
| Comparison | Lung Cancer Panel 6 [EGFR by Sequencing,ALK by IHC, ROS1 by FISH] |
Frequently Asked Questions
What is the cost of the Lung Cancer Panel 6 test?
What sample is required for this test?
Do I need to fast before the test?
How long does it take to get the results?
Is a doctor's prescription necessary?
What is the purpose of testing EGFR, ALK, and ROS1?
Can this test be done on a blood sample?
Is home sample collection available?
What is the turnaround time for reports?
Are there any risks associated with the biopsy?
What if the tumor content is insufficient?
Is this test covered by insurance?
Related Tests
B-Cell Rearrangement Detection Test
₹22,000Acute Lymphoblastic Leukemia (ALL) Cytogenetics Panel Test
₹20,000Epstein-Barr Virus Early RNA (EBER-ISH) In-Situ-Hybridization Test
₹6,000OncoPro NCCN Lung Cancer Panel with PD-L1 Test
₹140,400Acute Myeloid Leukemia (AML) Cytogenetics Panel Test
₹23,000AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test
₹6,000Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.